Why Is REVOLUTION MEDICINES (RVMD) Stock Down Today?

RVMD stock fell 6.29% to $207.25 in afternoon trading on Friday, reversing from a small opening gap higher. The decline followed a series of analyst price target increases and a recent FDA approval of its pancreatic cancer drug, Rasonque, which failed to sustain investor confidence amid broader selling pressure from insiders and a high short-term valuation.

What Happened

Revolution Medicines received FDA approval for Rasonque, a first-of-its-kind targeted therapy for pancreatic cancer, which triggered a wave of analyst upgrades in recent days. Guggenheim and UBS both raised their price targets for the stock, with Guggenheim setting a new $275 target and UBS raising its target to $265. Despite these developments, the stock opened slightly higher at $222.70 but quickly reversed course, hitting a session low of $207.00 by midday. The decline accelerated as insider selling continued, with CEO Mark Goldsmith and other insiders reporting sales on August 21. The stock closed the session near its low, with volume at 0.5 million shares, or 20% of its 3-month average.

What The Data Shows

The stock has traded between $35.64 and $224.31 over the past 52 weeks and is currently valued at a market cap of $46.2 billion. Despite the recent FDA milestone, the company remains unprofitable, with a trailing twelve-month EPS of -8.92 and a revenue decline of 97.2%. The stock has moved only 0.6% over the last eight sessions, from $216.00 to $217.40. Insiders have sold a total of $54.5 million in the last 90 days, with no insider purchases recorded. Additionally, the stock printed 26 fresh 52-week lows on August 28, indicating ongoing pressure from short sellers and profit-taking.

What To Watch

Revolution Medicines does not have an upcoming earnings date listed. Investors should monitor the breadth of analyst coverage and any further insider activity for signs of conviction in the stock’s long-term prospects.